This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Medicaid Drug Rebate Program (MDRP) Summit 2025
September 15-17, 2025
Delivered as a Hybrid EventFairmont Chicago Millennium Park, Chicago, IL

Content Hub - Insights into MDRP

Expert Guidance: Your Definitive Resource for Medicaid Drug Rebate Program Insights

Book your pass now!

Book by May 23 and SAVE up to $600!

Session Spotlights

Navigating the Intersection: 340B, IRA, MFP

  • This live stream examines how 340B programs intersect with the Inflation Reduction Act and Medicare Fair Pricing.
  • Learn optimization strategies for 340B pricing under IRA impacts, understand MFP reforms' effects on participation requirements, and discover compliance approaches across these overlapping policies.
  • The session also addresses PBM formulary decisions in the MFP landscape and strategies to maintain patient access.

340B Program Evolution, Court Decisions, Compliance Implications and Policy Developments

  • This session analyzes pharmaceutical import policies, including tariffs on products from China, India, and EU, and their cost impacts.
  • Explore "Made in America" requirements for FSS products, tariff policies' intersection with supply chain challenges, and strategies for managing cross-border product movements.
  • Track B addresses state-level pharmaceutical policy complexities.

IRA Implementation at the Crossroads: Strategic Decision Framework for 2026 and Beyond

  • This session examines the IRA's transition from implementation to mature operations, exploring necessary adjustments for commercial planning and portfolio optimization.
  • Learn how organizations are adapting beyond compliance, developing data-driven approaches for negotiations and contracting, and balancing short-term tactics with long-term strategy as the program expands to Part B drugs and additional therapeutic categories.

Recent OIG Evaluations Involving Prescription Drug Pricing, Payment, and Coverage

  • This session examines recent OIG investigations, audit findings, and enforcement actions in government pricing programs, highlighting upcoming enforcement priorities and compliance implications for pharmaceutical manufacturers.



Key topics being explored at MDRP Summit

expand_less

What are the key components of the Inflation Reduction Act (IRA) affecting pharmaceutical pricing?

The IRA introduces significant changes to drug pricing, including Medicare price negotiation authority, inflation rebate requirements, and redesign of Medicare Part D benefit. These provisions impact manufacturer pricing strategies, government price reporting, and overall market access approaches.

What's new at MDRP this year?

The 2025 pharmaceutical landscape faces unprecedented challenges with policy shifts affecting pricing and compliance requirements. As Medicare negotiations expand and regulations tighten, manufacturers risk significant penalties for compliance failures. The MDRP Summit offers critical peer benchmarking, regulatory access, and strategic guidance to navigate this complex transformation period.

Prior Attendee

Simply the best Medicaid conference!